Approval of Novartis’ ofatumumab delayed by FDA review extension

Novartis submitted the new drug application (NDA) for the drug under FDA’s fast track programme. Credit: Shutterstock.



  • Entresto (Sacubitril / Valsartan) for the Treatment of Heart Failure